RCS - Yourgene Health PLC - Partnership with NPH

Yourgene HealthAnnouncement

22/02/2021 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20210222:nRSV8078Pa&default-theme=true

RNS Number : 8078P  Yourgene Health PLC  22 February 2021

Reach / Non-Regulatory Announcement

 

Yourgene Health plc

("Yourgene" or the "Group" or the "Company")

 

Partnership with NPH

 

To provide COVID-19 testing service for Leeds Bradford Airport

 

Manchester, UK - 22 February 2021: Yourgene (AIM: YGEN), the international
molecular diagnostics group, announces that its partnership with Newcastle
Premier Health Limited(1) ("NPH"), a leading provider of independent medical
services in Newcastle and the North East, will supply COVID-19 PCR testing
services to Leeds Bradford Airport from the Company's laboratory in
Manchester.

 

Yourgene and NPH are partnering with Leeds Bradford Airport(2) ("LBA") to
offer an onsite COVID-19 service for departing and arriving passengers, and
for the local community.  NPH has successfully implemented a similar testing
service at Newcastle Airport and will now look to mirror that offering at LBA
, using Yourgene's Clarigene® SARS-CoV-2 assay and its high throughput
COVID-19 service laboratory in Manchester to test samples taken at the
airport.

 

Together NPH and Yourgene will be offering 'Test To Release' for arriving
international travellers, 'Fit to Fly' test certificates for departing
passengers, and also general PCR coronavirus testing for the general public
that live in the surrounding region. This testing service becomes available
today at the airport in anticipation of a relaxation of lockdown rules in the
near future. NPH is the sole provider of COVID-19 testing to LBA and Yourgene
is the sole COVID-19 testing provider to NPH for the LBA contract.

 

Yourgene Genomic Services is a UK Government approved COVID-19 private testing
provider for the Test to Release for International Travel scheme and for
general coronavirus testing, as announced by the Company on 24 December 2020.

 

Lyn Rees, CEO of Yourgene commented: "We are thrilled to be partnering with
NPH and Leeds Bradford Airport to offer our accurate, reliable and trusted
COVID-19 testing service. While the timing of any lockdown relaxations and
increases in passenger traffic are unclear at present, we are primed for when
these restrictions are lifted at Leeds Bradford and other travel hubs around
the country.

 

"We are proud to be part of the global effort to fight this pandemic by
offering a high-class Genomics Services laboratories to our partners."

 

 

(1 )Newcastle Premier Health Limited is a leading provider of independent
medical services in Newcastle and the North East. The Company's wide range of
medical services includes General Practice consultations, travel advice and
immunisations, occupational health assessments, medical screening, and work
specific medical assessments for pilots, divers, seafarers and offshore
workers.

 

(2) Leeds Bradford Airport (LBA) is a regional travel hub used by over 4
million travellers pre-pandemic.

 

 

 Yourgene Health plc                                                           Tel: +44 (0)161 669 8122

 Lyn Rees, Chief Executive Officer                                             investors@yourgene-health.com
 Barry Hextall, Chief Financial Officer
 Joanne Cross, Director of Marketing

 N+1 Singer (Joint Corporate Broker)                                           Tel: +44 (0)20 7496 3000
 Aubrey Powell / Tom Salvesen / George Tzimas

 Stifel Nicolaus Europe Limited (Joint Corporate Broker)                       Tel: +44 (0)20 7710 7600
 Nicholas Moore / Matthew Blawat / Ben Maddison

 Walbrook PR Ltd (Media and Investor Relations)  Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com
  Paul McManus / Lianne Cawthorne                                              Mob: 07980 541 893 / Mob: 07584 391 303

About Yourgene Health

Yourgene Health is an international molecular diagnostics group which develops
and commercialises genetic products and services. The group works in
partnership with global leaders in DNA technology to advance diagnostic
science.

 

Yourgene primarily develops, manufactures, and commercialises simple and
accurate molecular diagnostic solutions, for reproductive health, precision
medicine and now infectious diseases. The Group's flagship products include
non-invasive prenatal tests (NIPT) for Down's Syndrome and other genetic
disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests,
and a recent extension into the oncology space with DPYD genotyping.

 

The launch of Yourgene Genomic Services has enabled Yourgene to offer a global
laboratory service network equipped to be a full life-cycle partner for
clinical, research and pharmaceutical organisations to support partners at the
preclinical, clinical, and post-market stages to develop, manufacture, obtain
regulatory approval and commercialise new products and services. In addition,
Yourgene Genomic Services offers an NIPT and high throughput COVID testing
service.

 

In August 2020, Yourgene acquired Coastal Genomics, Inc., a sample preparation
technology company based in Vancouver, Canada, enabling the Company to extend
its offering and IP portfolio in the DNA sample preparation sector. The
acquisition increased Yourgene's geographical penetration into the US and
Canada, supplementing existing coverage in the UK, Europe, MEA and Asia.

 

Yourgene Health is headquartered in Manchester, UK with offices in Taipei,
Singapore, the US and Canada, and is listed on the London Stock Exchange's AIM
market under the ticker "YGEN". For more information visit
www.yourgene-health.com and follow us on twitter @Yourgene_Health.

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRATMMTTMTMTBAB